An AAV1 CMV-driven follistatin gene transfer therapy has been developed and tested in Phase l/ll clinical testing in DMD’s less severe allelic disease Becker MD (BMD) (Table 1) [87]. Here, FST is linked to Duchenne muscular dystrophy.